The US may be in Thanksgiving mode, but companies in other parts of the world continue to come forward with venture capital investment news, including China's Alphamab Oncology with a $100m Series A round.
Suzhou-based Alphamab said on Nov. 16 that the proceeds will fund global clinical development of its cancer drug pipeline, including a second-generation immuno-oncology asset, as well as expansion of its clinical and commercial teams and construction of a biologics manufacturing facility
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?